220 related articles for article (PubMed ID: 37032225)
1. Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey.
Igho-Osagie E; Brzozowski K; Jin H; Brown J; Williams MG; Puenpatom A
Clin Ther; 2023 May; 45(5):390-399.e4. PubMed ID: 37032225
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy.
Igho-Osagie E; Puenpatom A; Williams MG; Song Y; Yi D; Wang J; Berman R; Gu M; He C
J Manag Care Spec Pharm; 2023 May; 29(5):509-518. PubMed ID: 36989455
[No Abstract] [Full Text] [Related]
3. Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments.
Martínez-López-de-Castro N; Samartín-Ucha M; Paradela-Carreiro A; Pérez-Landeiro A; Inaraja-Bobo MT; Álvarez-Payero M; Castro-Núñez I; García-Beloso N; Robles-Torres D; López-López A; González-Costas S; Leboreiro-Enríquez B; Otero-Millán L; Yaiza Romero-Ventosa E; Casanova-Martínez C; Lorenzo-Lorenzo K; Regueira-Arcay AM; Vázquez-López C; Martínez-Reglero C; Piñeiro-Corrales G
J Clin Pharm Ther; 2021 Jun; 46(3):724-730. PubMed ID: 33368439
[TBL] [Abstract][Full Text] [Related]
4. Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data.
Lübbert C; Dykukha I; Pelz JP; Yearley H; Junker W; Gruber N; Escher S; Biereth K; Melnik S; Puschmann J
Drugs Context; 2023; 12():. PubMed ID: 37415918
[TBL] [Abstract][Full Text] [Related]
5. Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older.
Ranzani A; Oreni L; Agrò M; van den Bogaart L; Milazzo L; Giacomelli A; Cattaneo D; Gervasoni C; Ridolfo AL
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):193-201. PubMed ID: 29767640
[TBL] [Abstract][Full Text] [Related]
6. The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan.
Nusair MB; Al-Azzam SI; Arabyat RM; Amawi HA; Alzoubi KH; Rabah AA
Saudi Pharm J; 2020 Feb; 28(2):155-160. PubMed ID: 32042253
[TBL] [Abstract][Full Text] [Related]
7. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
8. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients.
Tseng A; Szadkowski L; Walmsley S; Salit I; Raboud J
Ann Pharmacother; 2013 Nov; 47(11):1429-39. PubMed ID: 24285760
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Drug-Related Problems in Chronic Kidney Disease Patients.
Shouqair TM; Rabbani SA; Sridhar SB; Kurian MT
Cureus; 2022 Apr; 14(4):e24019. PubMed ID: 35573572
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda.
Eneh PC; Hullsiek KH; Kiiza D; Rhein J; Meya DB; Boulware DR; Nicol MR
BMC Infect Dis; 2020 Aug; 20(1):572. PubMed ID: 32758158
[TBL] [Abstract][Full Text] [Related]
11. Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study.
Secoli SR; Figueras A; Lebrão ML; de Lima FD; Santos JL
Drugs Aging; 2010 Sep; 27(9):759-70. PubMed ID: 20809665
[TBL] [Abstract][Full Text] [Related]
12. Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.
Halloran MO; Boyle C; Kehoe B; Bagkeris E; Mallon P; Post FA; Vera J; Williams I; Anderson J; Winston A; Sachikonye M; Sabin C; Boffito M
Antivir Ther; 2019; 24(3):193-201. PubMed ID: 30700636
[TBL] [Abstract][Full Text] [Related]
13. Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain.
Cantudo-Cuenca MD; Gutiérrez-Pizarraya A; Pinilla-Fernández A; Contreras-Macías E; Fernández-Fuertes M; Lao-Domínguez FA; Rincón P; Pineda JA; Macías J; Morillo-Verdugo R
Sci Rep; 2021 Jun; 11(1):12414. PubMed ID: 34127740
[TBL] [Abstract][Full Text] [Related]
14. Potential drug-drug interactions between antiretroviral drugs and comedications, including dietary supplements, among people living with HIV: A clinical survey.
Tinggaard M; David KP; Gerstoft J; Hansen AE; Kirk O; Lebech AM; Lindhardt BØ; Rose MV; Ryom L; Weis N; Benfield T
HIV Med; 2023 Jan; 24(1):46-54. PubMed ID: 35521975
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.
Marzolini C; Elzi L; Gibbons S; Weber R; Fux C; Furrer H; Chave JP; Cavassini M; Bernasconi E; Calmy A; Vernazza P; Khoo S; Ledergerber B; Back D; Battegay M;
Antivir Ther; 2010; 15(3):413-23. PubMed ID: 20516560
[TBL] [Abstract][Full Text] [Related]
16. Potential drug-drug interactions in patients with indication for prophylactic implantation of a cardioverter defibrillator: a cross-sectional analysis.
Dornquast C; Dombrowski M; Zabel M; Willich SN; Reinhold T
BMC Health Serv Res; 2020 Mar; 20(1):271. PubMed ID: 32234046
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors.
Deutschmann E; Bucher HC; Jaeckel S; Gibbons S; McAllister K; Scherrer AU; Braun DL; Cavassini M; Hachfeld A; Calmy A; Battegay M; Cipriani M; Elzi L; Young J; Lopez-Centeno B; Berenguer J; Khoo S; Moffa G; Marzolini C;
Clin Infect Dis; 2021 Oct; 73(7):e2145-e2152. PubMed ID: 32634832
[TBL] [Abstract][Full Text] [Related]
18. The Prevalence of Drug-Drug Interactions with Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients in the Intensive Care Unit.
Johnston JP; Heavner MS; Liu M; Casal GLH; Akgün KM
J Pharm Pract; 2023 Apr; 36(2):322-328. PubMed ID: 34587846
[No Abstract] [Full Text] [Related]
19. Comorbidities, Age, and Polypharmacy Limit the Use by US Older Adults with Nocturia of the Only FDA-approved Drugs for the Symptom.
Suvada K; Plantinga L; Vaughan CP; Markland AD; Mirk A; Burgio KL; Erni SM; Ali MK; Okosun I; Young H; Goode PS; Johnson TM
Clin Ther; 2020 Dec; 42(12):e259-e274. PubMed ID: 33257091
[TBL] [Abstract][Full Text] [Related]
20. Potential drug-drug interactions in internal medicine wards in hospital setting in Pakistan.
Ismail M; Iqbal Z; Khattak MB; Khan MI; Arsalan H; Javaid A; Gul Q; Khan F
Int J Clin Pharm; 2013 Jun; 35(3):455-62. PubMed ID: 23483444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
